|
|||||
|
|
In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors |
|
| Affiliation: | 1. Department of Basic Sciences and Social Sciences, North-Eastern Hill University, Shillong 793022, Meghalaya, India;2. Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia;3. Department of Environment and Forest Resources, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea;4. Genetics Laboratory, Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia |
| Abstract: | |
| Keywords: | Coronaviruses Coronaviral main protease FDA approved drugs Ergotamine Dihydroergotamine COVID-19 SARS-CoV-2 SARS-CoV MERS-CoV 2019-nCoV |
| 本文献已被 ScienceDirect 等数据库收录！ | |